Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
$ 0.21
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Greatly undervalued vs peers
Data is available to registered users only
Data is available to registered users only
About
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's product pipeline includes CNCT19,...
Company Valuation
Based on key historical and expected multiples, the stock is greatly undervalued relative to its peers.
Data is available to registered users only
Buy
Sell